Insights From prIME Masterclass in Head & Neck Cancer - priME Oncology
Webcast
Webcast

Insights From prIME Masterclass in Head & Neck Cancer

Video Highlights of the Live Meeting in Taipei

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Hear from the experts during this webcast that includes highlights from prIME Masterclass in Head & Neck Cancer. Stay engaged with the most up-to-date management concepts and emerging treatment strategies for patients with squamous cell carcinoma of the head & neck (SCCHN).

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Jan 25, 2019

Expiration Date

Jan 25, 2019

Setting the stage—Multimodality treatment approach in head & neck (H&N) cancer: Current standards, challenges, and unmet needs
Jin-Ching Lin, MD, PhD

Advances in surgical management of SCCHN
Jenn-Ren Hsiao, MD, PhD

Keynote presentation—Reaching new heights in the management of H&N cancer: Evolving role of immunotherapy
Frederic Peyrade, MD

Contemporary management of locally advanced SCCHN
Sadamoto Zenda, MD, PhD

Induction therapy for locally advanced H&N cancer: Is there still a role?
Jin-Hyoung Kang, MD, PhD

Optimal treatment of recurrent/metastatic SCCHN: Front-line therapy and beyond
Ye Guo, MD

What can we expect in H&N cancer management in the near future?
Alexander Guminski, BSc, MBBS, FRACP, PhD

prIME Points™
Frederic Peyrade, MD

  • Alexander Guminski, BSc, MBBS, FRACP, PhDNorthern Sydney Cancer Centre
    Royal North Shore Hospital
    Sydney, New South Wales, Australia
  • Ye Guo, MDTongji University, Shanghai East Hospital
    Shanghai, China
  • Jenn-Ren Hsiao, MD, PhDNational Cheng-Kung University Hospital
    Tainan, Taiwan
  • Jin-Hyoung Kang, MD, PhDCatholic University of Korea
    Seoul St Mary’s Hospital
    Seoul, South Korea
  • Jin-Ching Lin, MD, PhDTaichung Veterans General Hospital
    Taichung, Taiwan
  • Pei-Jen Lou, MD, PhDNational Taiwan University Hospital
    National Taiwan University College of Medicine
    Taipei, Taiwan
  • Frederic Peyrade, MDAntoine Lacassagne Center
    Nice, France
  • Sadamoto Zenda, MD, PhDNational Cancer Center Hospital East
    Chiba, Japan

This educational activity is specifically designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with H&N cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the importance of multidisciplinary care in H&N cancer and how to best apply it for optimal outcomes
  • Identify the current role of immunotherapy in the management of SCCHN and ongoing research strategies including combinations of conventional therapies and immunotherapies
  • Apply multidisciplinary approaches for managing patients with HPV+ and HPV- locally advanced SCCHN, elderly patients, and those unsuitable for platinum-based chemoradiation
  • Select optimal treatment sequence for patients with recurrent/metastatic SCCHN
  • Utilize current knowledge to manage complex clinical cases and toxicities related to the management of H&N cancer
  • Explain current and emerging therapeutic options for advanced SCCHN after progression on immunotherapy

This educational activity is supported by a grant from Merck KGaA, Darmstadt, Germany.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Guminski has disclosed consulting fees from Bristol-Myers Squibb, Merck KgA, Pfizer, Regeneron, Roche, and Sun Pharma. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Guo has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hsiao has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kang has disclosed consulting fees from AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd.; and Chong Kun Dang Pharmaceutical Corp. He also disclosed membership on advisory committees or review panels for AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical Co., Ltd.; Chong Kun Dang Pharmaceutical Corp; and Eli Lilly. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lin has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lou has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Peyrade has disclosed board membership with and independent contracting for Merck KGaA. He also received consulting fees from Merck Sharp & Dohme. He also disclosed honoraria for promotional speaker’s bureaus from Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Zenda has disclosed honoraria for promotional speaker’s bureaus from Merck Serono. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD, MSc (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.